Telo Genomics (TSXV:TELO) Tax Provision : C$0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Tax Provision?

Telo Genomics's tax provision for the three months ended in Dec. 2024 was C$0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was C$0.00 Mil.

Telo Genomics Tax Provision Historical Data

The historical data trend for Telo Genomics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Tax Provision Chart

Telo Genomics Annual Data

Trend

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Tax Provision

Get a 7-Day Free Trial

Telo Genomics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

Telo Genomics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Telo Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

TDSGF:USA

Address

101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7

Website

https://www.telodx.com

Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.

Executives